PricewaterhouseCoopers is a leading medical device company, focusing on high-growth and high-profit segments of China's medical device industry. The Group's current business segments are infusion devices, blood purification products and regenerative medical biomaterials, and it has firmly taken a leading position in the market with strong R&D capabilities and a complete distribution network. The company's shares were successfully listed on the main board of the Stock Exchange on November 8, 2013, thereby enabling PricewaterhouseCoopers to enter international capital markets and establish a platform for the rapid development of its business. — The Group is a leading company in the infuser business in China. The Group's products include non-PVC infusion sets, precision filter infusion sets, light-proof infusion sets, intravenous needle products, insulin needles and insulin pens. The Group was one of the first manufacturers approved by the China Food and Drug Administration to produce precision filter infusion sets, and was one of the first three manufacturers approved by the China Food and Drug Administration to manufacture non-PVC infusion sets. The Group also has an exclusive patented non-PVC double-layer tube infusion device design. — The Group is a leading company in the field of blood purification business in China. The Group's products include high-throughput hemodialysers, low-throughput hemodialyzers, hemodialysis filters, and hemoperfusion devices. The Group is the first manufacturer in China to obtain a registration certificate for a high-throughput hemodialyzer. —The Group has strong R&D capabilities in the regenerative medical biomaterials sector. It uses leading, latest-generation tissue regeneration material technology, a complete product pipeline, and a wide range of application scenarios, including hernia repair, burns, oral repair, breast repair, injectable cosmetology, etc.
No Data
No Data